Cash & equivalents decreased 98.1%
Cash & equivalents changed -98.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed -98.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed -96.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed -92.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +314.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Research & development changed -94.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed +24.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Research & development changed -83.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Stock-based compensation changed -93.5% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Shares outstanding changed -46.7% from the comparable as-filed period. The change ranks at the 50th percentile of 6 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.